PMID- 24284025
OWN - NLM
STAT- MEDLINE
DCOM- 20140527
LR  - 20220408
IS  - 1941-3297 (Electronic)
IS  - 1941-3289 (Linking)
VI  - 7
IP  - 1
DP  - 2014 Jan
TI  - Prognostic effect of high-sensitive troponin T assessment in elderly patients 
      with chronic heart failure: results from the CORONA trial.
PG  - 96-103
LID - 10.1161/CIRCHEARTFAILURE.113.000450 [doi]
AB  - BACKGROUND: The incremental prognostic value of high-sensitive troponin T 
      (hs-cTnT) in heart failure (HF) beyond that of high-sensitivity C-reactive 
      protein and amino-terminal probrain natriuretic peptide is debated. We examined 
      the prognostic value of hs-cTnT in a subgroup of patients from the Controlled 
      Rosuvastatin Multinational Trial in HF (CORONA) study. METHODS AND RESULTS: 
      Hs-cTnT as a risk factor for the primary end point (cardiovascular death, 
      nonfatal myocardial infarction, and nonfatal stroke; n=356), as well as all-cause 
      mortality (n=366), cardiovascular mortality (n=299), and the composite of 
      cardiovascular mortality and hospitalization from worsening of HF (n=465), was 
      investigated in 1245 patients (>/=60 years; New York Heart Association [NYHA] class 
      II-IV, ischemic systolic HF) randomly assigned to 10 mg rosuvastatin or placebo. 
      In multivariable analyses, adjusting for left ventricular ejection fraction, NYHA 
      class, age, body mass index, diabetes mellitus, sex, intermittent claudication, 
      heart rate, estimated glomerular filtration rate, apolipoprotein B/apolipoprotein 
      A-1 ratio, amino-terminal probrain natriuretic peptide, high-sensitivity 
      C-reactive protein, and hs-cTnT (both dichotomized according to the 99th 
      percentile and as a continuous variable) was associated with all end points 
      (primary end point: hazard ratio, 1.87 and 1.51, respectively, per SD change; 
      P<0.001; all other end points: hazard ratio, 1.39-1.70). However, improved 
      discrimination as assessed by C-statistics was only seen for the primary end 
      point and all-cause mortality. CONCLUSIONS: Elevated hs-cTnT levels provide 
      strong and independent prognostic information in older patients with chronic 
      ischemic HF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. 
      Unique identifier: NCT00206310.
FAU - Gravning, Jorgen
AU  - Gravning J
AD  - Department of Cardiology.
FAU - Askevold, Erik T
AU  - Askevold ET
FAU - Nymo, Stale H
AU  - Nymo SH
FAU - Ueland, Thor
AU  - Ueland T
FAU - Wikstrand, John
AU  - Wikstrand J
FAU - McMurray, John J V
AU  - McMurray JJ
FAU - Aukrust, Pal
AU  - Aukrust P
FAU - Gullestad, Lars
AU  - Gullestad L
FAU - Kjekshus, John
AU  - Kjekshus J
CN  - CORONA Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00206310
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20131127
PL  - United States
TA  - Circ Heart Fail
JT  - Circulation. Heart failure
JID - 101479941
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Peptide Fragments)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Troponin T)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticholesteremic Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Chronic Disease
MH  - Female
MH  - Fluorobenzenes/*therapeutic use
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*epidemiology
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Pyrimidines/*therapeutic use
MH  - Risk Factors
MH  - Rosuvastatin Calcium
MH  - Sensitivity and Specificity
MH  - Stroke/*epidemiology
MH  - Sulfonamides/*therapeutic use
MH  - Survival Rate
MH  - Troponin T/*blood
OTO - NOTNLM
OT  - heart failure
OT  - prognosis
OT  - risk assessment
OT  - troponin T
EDAT- 2013/11/29 06:00
MHDA- 2014/05/28 06:00
CRDT- 2013/11/29 06:00
PHST- 2013/11/29 06:00 [entrez]
PHST- 2013/11/29 06:00 [pubmed]
PHST- 2014/05/28 06:00 [medline]
AID - CIRCHEARTFAILURE.113.000450 [pii]
AID - 10.1161/CIRCHEARTFAILURE.113.000450 [doi]
PST - ppublish
SO  - Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. 
      Epub 2013 Nov 27.